bioAffinity Technologies posts record monthly volume for CyPath Lung test
bioAffinity Technologies (BIAF) reported 235 CyPath Lung tests in October, a 29% increase from last year. The company attributes growth to expanded physician adoption and commercial efforts. CyPath Lung uses AI to assess lung cancer risk, with 92% sensitivity and 87% specificity in trials. BIAF is also advancing R&D for asthma, COPD, and skin cancer treatments.
How this was made
The 30-second read
Why it matters
The record test volume underscores successful commercial rollout and validates the AI‑driven platform, which could accelerate revenue growth and attract partnership interest.
Market read
First disclosure of significant usage growth for BioAffinity's flagship test, offering a fresh catalyst for the stock.
What to watch
Potential regulatory hurdles for new indications and competition from larger diagnostic firms could temper expectations.
Background
BioAffinity Technologies focuses on AI‑enhanced flow cytometry tests for early detection of lung disease, recently expanding its pipeline to asthma and COPD.
Ticker impact
BioAffinity reported a record 235 CyPath Lung tests in October, a 29% increase YoY and 45% of Q3 volume, indicating strong demand growth.
likely upward pressure as investors price in higher future sales
First‑time disclosure of record usage and strong clinical performance; micro‑cap biotech typically reacts positively to demand growth.
Market effects
Highlights growing interest in non‑invasive lung cancer diagnostics, potentially benefiting peers in liquid biopsy and AI‑driven diagnostics.
U.S. biotech sector may see modest uplift as a micro‑cap demonstrates commercial traction.
Limited to niche diagnostic market; no broad macro impact.
Counterpoint
Volume growth may be temporary if reimbursement or payer coverage issues arise, limiting long‑term upside.
Key entities
- ExecutiveMaria Zannes
CEO of BioAffinity who highlighted the volume growth and expansion plans.
